Transforming cardiometabolic health: Why LPLDL® is leading probiotic-based product innovation

Modern medicine has successfully tackled infectious diseases, but non-communicable lifestyle diseases, including cardiometabolic syndrome (CMS), are not only on the rise but are viewed as one of the most pressing global health concerns of our time.

CMS typically refers to a group of common and often preventable chronic conditions that affect the cardiovascular system, in particular the heart, circulation, blood vessels, and metabolic system, with insulin resistance, dyslipidemia, hyperuricemia, and hypertension key symptoms.

Here’s a sobering fact: People with CMS are twice as likely to die from coronary heart disease and three times more likely to have a heart attack or stroke than those who do not have the syndrome. As its prevalence increases, CMS will continue to have a significant impact on individuals’ ability to live their years in health.

What’s Driving the Rise in Cardiometabolic Risk?

While genetic susceptibility is essential in developing CMS, the syndrome is relatively uncommon in consumers who are within normal weight and moderately active – making weight loss and increased physical activity the first line of defence in managing metabolic disturbances.

But there are other factors at play too. Research shows that the environment we live in can contribute to CMS risk with an article in the health journal Circulation noting that urban environments contribute significantly to the rising burden of cardiometabolic diseases. This is primarily due to air and noise pollution, chemical exposure, physical inactivity, and a lack of green spaces. Other research still is focused on the effects of chronic insomnia on the metabolic system.

A study in the scientific journal nature found that that chronic insomnia is associated with a higher risk of CMS. The study investigated the impact of the gut microbiota-bile axis and highlighted the positive association that exists between chronic insomnia and CMS. The study also pointed to a direct link between physiological responses to stress that could result in internal dysregulation and increased cardiometabolic risk. Education seems to play a significant part too. A study conducted with 8, 449 subjects from the Czech Republic, i as the strongest determinant of cardiovascular mortality, followed by hypertension and smoking. But what does this tell us about other geographies?

Mapping the geography of CMS

Research shows that countries with the highest rates of CMS are situated in the Middle East, North America, and Asia. In Saudi Arabia, a cross-sectional study reported a cardiometabolic syndrome prevalence of 39.8% using medical guidelines, with high rates of obesity and diabetes, coupled with urbanisation were the biggest risk factors.

In the US, the prevalence of metabolic syndrome is reported at 34.3% with high obesity rates, sedentary lifestyles, and diets rich in processed foods contributing factors. Meanwhile, China, where instances of CMS have historically been low, is now seeing rates of 21.3%, , primarily due to rapid economic development, and the shift towards Western diets and an inactive lifestyle.

How the Market Is Evolving Toward Natural Cardiovascular Solutions

With advances in wearable technology and the democratisation of at-home biomarker testing, consumers now have the power to change their health for the better. In this space, we will continue to see informed consumers concerned about their health investing in natural alternatives and preventatives as opposed to traditional treatments, which is contributing to the boom in the cardiovascular supplements market.

Valued at $12 billion in 2024, sales of cardiovascular supplements are on track to hit $18.76 billion by 2032, growing at a steady 6.1% CAGR.

Here Asia Pacific leads the charge, holding a dominant 39% market share in 2024. It is also noteworthy to mention that natural supplements emerged as the frontrunner in 2023, commanding a dominant 64% share of market growth. In Europe, this buoyancy will be further supported by by EFSA as it updates its Guidance on the scientific principles and data required to assess the safety and relative bioavailability of new substances. This will have a positive impact on streamlining approval processes, further fuelling innovation in the sector.

These facts have led to renewed interest in natural and functional ingredients that could shape next-generation cardiometabolic health solutions:

Omega-3 Fatty Acids – Can assist in lowering triglyceride levels and support insulin function
Berberine – A powerful plant-based bioactive, berberine is widely noted for its ability to regulate blood sugar, improve lipid profiles, aid weight management, and boost metabolic health.
Coenzyme Q10 – As a crucial antioxidant, CoQ10 supports mitochondrial function, enhances endothelial health, and combats oxidative stress—potentially improving cardiovascular health and mitigating CMS-related conditions.
ProBiotix’ LP_LDL® – A patent protected, naturally occurring probiotic strain of the bacterial species Lactobacillus plantarum that can target cardiometabolic health markers including cholesterol, apolipoprotein B, and blood pressure.

Disclaimer – This information has been compiled to the best of ProBiotix Health’s knowledge and expertise and is intended for informational purposes only

Inside the Science: What Makes LPLDL® Different

What distinguishes LP_LDL® from other cardiometabolic ingredients and probiotic strains is its positive effect on improving cholesterol levels, blood pressure, and vascular health by utilising the gut-liver axis. Human intervention studies, conducted at the University of Roehampton and the University of Reading in the UK indicate that a daily intake of LP_LDL® can have a marked effect on multiple cardiometabolic health biomarkers, particularly cholesterol, Apolipoprotein B, triglycerides, and blood pressure.

This is in part due to its superior salt hydrolase activity. Bile salts are now considered a crucial link between the gut microbiome and cardiometabolic health. LP_LDL® reduces bile salt reabsorption in the liver. This leads to an increase in blood cholesterol uptake by the liver to replenish and restore its bile acid pool.

LP_LDL^® is a great solution for brands wanting to tap into growth in the cardiometabolic supplements market. LP_LDL^® is stable when combined with most other active ingredients, making it a versatile option, and offers Supported Structure Function US* health claims including:

‘Maintains cholesterol levels already in the normal range’
‘Supports normal LDL and HDL cholesterol’
‘Has a positive effect on cholesterol levels within the normal range’

Not All Cardiometabolic Health Ingredients Are Created Equal

We’re unveiling the science that sets us apart; head-to-head comparisons, clinical data, and our patented probiotic strain LP_LDL^®, all reshaping how brands formulate for cardiometabolic health.

See What the Data Really Says

We’ve analysed the landscape and we’re sharing the results. Our new insights document covers the latest innovation trends, ingredient performance data, and where LP_LDL^® stands among leading cardiovascular ingredients. Download the insights below.

Innovation, Backed by Experience: ProBiotix’s Vision for Adding Life to Years

At ProBiotix Health we remain committed to accelerating scientifically validated, probiotic-based microbiome product solutions to support cardiometabolic health and healthy ageing. This commitment is driven by our highly experienced management team, offering a combined experience of 120+ years in the microbiome sector.

Get in touch with a ProBiotix Expert to learn how LP_LDL® can bring innovation and scientific credibility to your product portfolio Contact Us – ProBiotix Health

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.